{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-025793","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2026-08-05T12:02:32+00:00","discovered_at":"2026-08-05T12:05:02.502640+00:00","generated_at":"2026-08-05T12:05:15.104325+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"UroGen Q2 2026: ZUSDURI revenue $50.4M (+73% QoQ); net loss narrows to $14.4M","bullets":["Total revenue $72.5M (Q2 2026) vs $24.2M (Q2 2025), driven by ZUSDURI launch.","ZUSDURI net product revenue $50.4M, 73% QoQ growth; 1,444 activated sites, 452 prescribers.","JELMYTO revenue $22.0M (Q2 2026) vs $24.2M (Q2 2025); FY guidance $97-101M.","Net loss $14.4M ($0.28/share) vs $49.9M ($1.05) in Q2 2025; cash $108.0M.","UGN-103 NDA on track for Q3 2026; new patent allowance extends ZUSDURI protection to July 2044."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-025793","json":"https://secwatch.observer/filing/0001437749-26-025793.json","markdown":"https://secwatch.observer/filing/0001437749-26-025793.md","text":"https://secwatch.observer/filing/0001437749-26-025793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/0001437749-26-025793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/urgn20260730_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T12:05:15.104325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}